Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy 

Teva has entered an agreement to act as the stalking horse bidder for BioXcel Therapeutics' neuroscience asset BXCL501, offering an upfront payment of $57.5 million plus up to $67.5 million in contingent payments. The dexmedetomidine sublingual film is currently under FDA review with a PDUFA target action date of November 14, 2026, for the at-home treatment of agitation associated with schizophrenia or bipolar disorder.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.